Insights from Multi-Omics on Maternal-Fetal Immune Tolerance in Recurrent Pregnancy Loss: Mechanisms, Integration Challenges, and Clinical Implications - Summary - MDSpire
Advertisement
Insights from Multi-Omics on Maternal-Fetal Immune Tolerance in Recurrent Pregnancy Loss: Mechanisms, Integration Challenges, and Clinical Implications
To summarize recent advances in multi-omics technologies applied to recurrent pregnancy loss (RPL) and to highlight immune–metabolic–microbiome interactions at the maternal–fetal interface.
Key Findings:
Multi-omics profiling reveals mechanistic heterogeneity in RPL, including chromosomal abnormalities, aberrant methylation patterns, and altered cellular composition.
Single-cell and spatial transcriptomics show disrupted communication among immune cells at the maternal–fetal interface.
Proteomic and metabolomic studies identify immune–metabolic signatures linked to impaired trophoblast function.
Integration of multi-omics datasets may enhance RPL subtype classification and risk prediction.
Interpretation:
The integration of multi-omics approaches provides a comprehensive understanding of the complex biological networks involved in RPL, which may lead to improved risk assessment and individualized management strategies.
Limitations:
Current studies often have small cohort sizes, particularly in single-cell datasets.
There is cross-platform heterogeneity and insufficient longitudinal validation.
Lack of multicenter reproducibility limits the generalizability of findings.
Conclusion:
Future research should focus on standardized multi-omics pipelines and immune-centric analytical frameworks to enhance the robustness and translational relevance of RPL studies.
